SCHEMBL4180372

SCHEMBL4180372

COc1ccc(S(=O)(=O)NC(C)C(C)NS(=O)(=O)c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.61
LMNA P02545 3/20 0.61
HTT P42858 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
ALDH1A1 P00352 3/20 0.60
MAPK1 P28482 3/20 0.59
POLB P06746 1/20 0.59
TSHR P16473 1/20 0.59
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
FFAR4 Q5NUL3 1/20 0.56
PDE4A P27815 2/20 0.55
PDE4B Q07343 2/20 0.55
PDE4C Q08493 2/20 0.55
PDE4D Q08499 2/20 0.55
KEAP1 Q14145 1/20 0.55
NFE2L2 Q16236 1/20 0.55
TP53 P04637 1/20 0.54
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24040870 0.90 ALDH1A1 (0.74) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL7441253 0.84 KMT2A (0.56) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL4608475 0.84 LMNA (0.67) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL4184408 0.83 KMT2A (0.58) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL4184412 0.83 KMT2A (0.58) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL4609744 0.82 LMNA (0.65) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL6927327 0.82 LMNA (0.69) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL4186954 0.82 KMT2A (0.64) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL4186951 0.82 KMT2A (0.64) KMT2ALMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL15880603 0.79 CA1 (0.73) KMT2ALMNAHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A KMT2A 3729/4885LMNA 3674/4885HTT 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.